Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lovely Professional Univ. androgen receptor compound MS14: sourced facts only. name: "Moreover, ROS production assay and androgen receptor inhibition assay has shown promising results for MS-14 as compared to standard drug." [PMID:41061516]; target: "Moreover, ROS production assay and androgen receptor inhibition assay has shown promising results for MS-14 as compared to standard drug." [PMID:41061516]; developer: "School of Pharmaceutical Sciences, Lovely Professional University, Jalandhar-Delhi G.T. Road, Phagwara, Punjab 144411, India." [PMID:41061516]; stage: "Importantly, validation in androgen-sensitive LNCaP cells confirmed that MS14 retained significant antiproliferative activity, achieving up to 78.2 % inhibition at 1000 nM, thereby supporting its dual AR-dependent and AR-independent modes of action." [PMID:41061516]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Lovely Professional Univ. androgen receptor compound MS14.